Your session is about to expire
← Back to Search
Ondansetron Premedication for Juvenile Idiopathic Arthritis (OPT-JIA Trial)
OPT-JIA Trial Summary
This trial will evaluate if pre-medicating with Ondansetron reduces nausea and vomiting in children taking methotrexate for Juvenile Arthritis.
OPT-JIA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowOPT-JIA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 139 Patients • NCT02001987OPT-JIA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My family cannot fill out forms in English or French.I am taking medication that affects my heart rhythm or electrolyte levels.I am currently taking medication that affects my serotonin levels.I am between 4 and 16 years old.I have been diagnosed with juvenile idiopathic arthritis.I have been diagnosed with Long-QT syndrome.I am starting methotrexate for JIA and am not pregnant, breastfeeding, or planning to become pregnant. I use effective birth control.I have signed a consent form to participate.I have previously used methotrexate.
- Group 1: Ondansetron as needed
- Group 2: Ondansetron premedication
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What pathological conditions does Methotrexate commonly address?
"Methotrexate is a viable therapeutic option for managing multiple sclerosis, pharmacotherapy regimens, and advance directives."
Are there any eligibility criteria I must satisfy to join this research program?
"The current clinical trial is enrolling 176 minors aged 4-16 with juvenile arthritis. To be eligible, they must commence methotrexate treatment and provide written consent to participate in the CAPRI JIA Registry. Additionally, female participants of child bearing potential who are taking methotrexate must practice highly effective contraception or abstain from sexual activity while on the drug."
Are there multiple locales in the United States where this research is taking place?
"This experiment is being conducted by 14 sites, with some of these located in Montréal, London, and Ottawa. For the comfort of participants it is recommended to pick a medical centre closest to home for ease of travel requirements when enrolling."
What is the current quota for participants in this research experiment?
"Indeed, the information on clinicaltrials.gov corroborates that this experiment is actively searching for research participants. This trial was initially posted on August 2nd 2019 and has been recently updated on October 29th 2021. The study requires 176 candidates to be recruited from 14 distinct locations."
Does this experimental research include mature adults?
"As per the accepted criteria, only patients aged 4 to 16 can be admitted into this medical trial."
Are any new participants being enrolled in this trial currently?
"Affirmative. According to clinicaltrials.gov, this medical experiment which was initially reported on August 2nd 2019 is currently enrolling participants. A total of 176 volunteers are needed across 14 sites."
Are there any other investigations into the use of Methotrexate?
"Presently, 478 clinical trials are assessing the utility of methotrexate. Of those in progress, 141 have entered Phase 3. While much of this research is conducted at Woolloongabba, Queensland, there are 20336 sites running their own respective studies on Methotrexate worldwide."
Share this study with friends
Copy Link
Messenger